Trulicity (Dulaglutide):
Trulicity is a once-weekly injectable medication used to manage type 2 diabetes in adults. Its active ingredient, dulaglutide, is a GLP-1 receptor agonist that mimics the action of the natural hormone GLP-1. By binding to GLP-1 receptors, Trulicity stimulates insulin release in response to meals, inhibits glucagon secretion (which helps prevent the liver from producing too much glucose), and slows gastric emptying, leading to improved blood sugar control. Additionally, Trulicity has been shown to reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors .drugs.com+2trulicity.lilly.com+2drugs.com+2

Trulicity is administered as a subcutaneous injection once a week, with or without food. The typical starting dose is 0.75 mg, which may be increased to 1.5 mg for additional glycemic control. It is important to note that Trulicity is not suitable for individuals with type 1 diabetes or diabetic ketoacidosis. Common side effects include nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. Serious side effects can include pancreatitis, kidney problems, severe allergic reactions, and gallbladder issues. Trulicity also carries a boxed warning regarding the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on animal studies . Therefore, it is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. As with any medication, it is essential to use Trulicity under the guidance of a healthcare provider to ensure safety and efficacy.